Modern humanity wades daily through various radiations, resulting in frequent exposure and
causing potentially important biological effects. Among them, the brain is the organ most …

Glioma is often referred to as one of the most dreadful central nervous system (CNS)-specific
tumors with rapidly-proliferating cancerous glial cells, accounting for nearly half of the brain …

Despite major advances in therapy, cancer continues to be a leading cause of mortality. In
addition, toxicities of traditional therapies pose a significant challenge to tolerability and …

Glioblastoma remains as the most common and aggressive malignant brain tumor, standing
with a poor prognosis and treatment prospective. Despite the aggressive standard care …

Tumor treating fields (TTFields) is a noninvasive, regional antimitotic treatment modality that
has been approved for the treatment of recurrent glioblastoma by the US FDA and has a CE …

Abstract Treatment with alternating electric fields at an intermediate frequency (100–300
kHz), referred to as tumor treating fields (TTF) therapy, inhibits cancer cell proliferation. In the …

Glioblastoma is the most common and aggressive form of intrinsic brain tumor with a very
poor prognosis. Thus, novel therapeutic approaches are urgently needed. Tumor-treating …

Recurrent glioblastoma multiforme (GBM) is a highly aggressive cancer with poor prognosis,
and an overall survival of 6 to 7 months with optimal therapies. The NovoTTF-100A™ …

Abstract Background Tumor Treating Fields (TTFields), low intensity alternating electric
fields with antimitotic activity, have demonstrated survival benefit in patients with …

Glioblastoma (GBM) is a challenging cancer with poor prognosis. The classical standard for
treatment is safe resection, followed by concurrent chemoradiotherapy with subsequent …